<DOC>
	<DOCNO>NCT00001114</DOCNO>
	<brief_summary>Primary : To evaluate safety , toxicity , antitumor activity two dos interferon alfa-2b ( IFN-alpha ) combine fix dose didanosine ( ddI ) patient Kaposi 's sarcoma associate HIV infection . Secondary : To evaluate effect combine IFN-alpha ddI treatment HIV expression marker immune function . Previous study show IFN-alpha induce regression Kaposi 's sarcoma suppression HIV patient . Although various trial use IFN-alpha combination nucleoside analogue zidovudine demonstrate high degree antitumor activity evidence HIV suppression , overlap toxicity ( primarily neutropenia ) two agent proven dose-limiting . The toxicity profile ddI suggest drug may better tolerate zidovudine combine IFN-alpha .</brief_summary>
	<brief_title>The Safety Effectiveness Interferon Alfa-2B Plus Didanosine Patients With Kaposi 's Sarcoma</brief_title>
	<detailed_description>Previous study show IFN-alpha induce regression Kaposi 's sarcoma suppression HIV patient . Although various trial use IFN-alpha combination nucleoside analogue zidovudine demonstrate high degree antitumor activity evidence HIV suppression , overlap toxicity ( primarily neutropenia ) two agent proven dose-limiting . The toxicity profile ddI suggest drug may better tolerate zidovudine combine IFN-alpha . Up 90 patient randomize receive either low high dos IFN-alpha ( 1 10 million Units/day ) combination fix dose ddI . Fourteen patient initially enter dose level . If objective antitumor response observe among first 14 patient give dose , patient enter treatment arm . If one antitumor responses see give dose , 45 patient may enter treatment arm . Patients must complete least 4 week study therapy consider evaluable tumor response . Treatment continue tumor progression unacceptable toxicity occur . PER AMENDMENT 9/19/96 : NOTE - After 16 week treatment subject may receive FDA approved antiretroviral drug regimen addition place ddI .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis candidiasis herpes simplex . Up 14 day metronidazole . Recombinant erythropoietin . GCSF ( severe case neutropenia ) . Isoniazid treatment TB give conjunction pyridoxine . Required patient CD4 count &lt; 200 cells/mm3 : Prophylaxis PCP . PER AMENDMENT 9/19/96 : After first 16 week combine IFN alpha2b ddI treatment subject may discretion investigator receive FDA approve antiretroviral drug regimen addition place ddI . Patients must : Positive antibody HIV . Biopsyproven Kaposi 's sarcoma ( least 5 measurable lesion , least 1 measurable cutaneous lesion ) involve skin , lymph node , oral cavity , asymptomatic lesion GI tract require systemic chemotherapy . Lung involvement Kaposi 's sarcoma excludes . Consent parent guardian le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Concurrent opportunistic infection B symptom include unexplained fever , night sweat , weight loss &gt; 10 percent , diarrhea last 2 week . Visceral ( nonnodal ) Kaposi 's sarcoma require cytotoxic chemotherapy . Severe ( &gt; 2+ ) tumorassociated edema . Concurrent neoplasia basal cell carcinoma , anogenital intraepithelial neoplasia . Current clinical evidence peripheral neuropathy ( = &gt; grade 1 ) , pancreatitis , intractable diarrhea , active seizure disorder well controlled antiseizure medication . Significant symptomatic cardiac disease . Medical contraindication . Concurrent Medication : Excluded : Other investigational , antiviral , immunomodulating , antitumor agent . Drugs associate peripheral neuropathy ( ddI ) . PER AMENDMENT 9/19/96 : Other antiretroviral agent may take first 16 week combine IFN alpha2b ddI treatment . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : Opportunistic infection B symptom include unexplained fever , night sweat , weight loss &gt; 10 percent , diarrhea last 2 week . Prior grade 3 4 toxicity attribute ddI therapy . Prior history peripheral neuropathy ( = &gt; grade 1 ) , pancreatitis , intractable diarrhea , active seizure disorder well controlled antiseizure medication . History myocardial infarction ventricular arrhythmia . Prior Medication : Excluded : Prior IFNalpha . Corticosteroids , biological response modifier , cytotoxic chemotherapy , know neurotoxic drug ( ddI ddC ) within 30 day prior study entry . Therapy antiretroviral drug ( ddI ) within 7 day prior study entry . Prior Treatment : Excluded : Radiation therapy within 30 day prior study entry . Risk Behavior : Alcohol consumption strongly discourage . Patients consider noncompliant exclude .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Interferon-alpha</keyword>
</DOC>